Overview

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients who have advanced hematologic cancer.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Cytarabine
Fludarabine
Fludarabine phosphate
Criteria
DISEASE CHARACTERISTICS: Histologically proven advanced hematologic malignancy unsuitable
for standard allogeneic bone marrow transplantation One of the following types: Refractory
or relapsed acute myelogenous or lymphocytic leukemia Over 55 years Chronic myelogenous
leukemia and failed interferon treatment Over 55 years Lymphoma, chronic lymphocytic
leukemia, Hodgkin's disease, or multiple myeloma: Refractory OR More than 2 relapses OR
Relapse after autologous peripheral blood stem cell transplantation Myelodysplastic
syndrome other than refractory anemia Severe aplastic anemia Under 55 years and either
organ dysfunction or not eligible for standard allogeneic bone marrow transplant due to one
or more of the following: Chronic hepatitis LVEF less than 50% Karnofsky less than 70%
Unrelated matched donor available

PATIENT CHARACTERISTICS: Age: See Disease Characteristics Adult Performance status: See
Disease Characteristics Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Not
specified Hepatic: See Disease Characteristics SGOT/SGPT no greater than 4 times upper
limit of normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: See Disease
Characteristics Pulmonary: DLCO at least 50% predicted Other: Not pregnant or nursing
Negative pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not
specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
specified